This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis patients in Latin America with an inadequate response to non-biologic DMARDs.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT02011334?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
